Dianthus Therapeutics, Inc.
DNTH
$85.74
-$0.41-0.48%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -79.52% | -67.35% | -42.64% | 17.87% | 102.36% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -79.52% | -67.35% | -42.64% | 17.87% | 102.36% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -79.52% | -67.35% | -42.64% | 17.87% | 102.36% |
| SG&A Expenses | 47.79% | 37.43% | 36.72% | 18.19% | 24.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.69% | 66.49% | 62.44% | 84.92% | 100.98% |
| Operating Income | -63.22% | -74.68% | -69.24% | -88.94% | -100.90% |
| Income Before Tax | -72.40% | -91.05% | -88.32% | -102.46% | -100.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -72.40% | -91.05% | -88.32% | -102.46% | -100.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -72.40% | -91.05% | -88.32% | -102.46% | -100.61% |
| EBIT | -63.22% | -74.68% | -69.24% | -88.94% | -100.90% |
| EBITDA | -63.26% | -74.73% | -69.29% | -89.01% | -100.99% |
| EPS Basic | -43.40% | -58.36% | -39.78% | 41.27% | 83.75% |
| Normalized Basic EPS | -38.00% | -54.26% | -42.54% | 37.39% | 82.55% |
| EPS Diluted | -43.40% | -58.36% | -39.78% | 41.27% | 83.75% |
| Normalized Diluted EPS | -38.00% | -54.26% | -42.54% | 37.39% | 82.55% |
| Average Basic Shares Outstanding | 19.62% | 19.52% | 32.58% | 79.20% | 207.72% |
| Average Diluted Shares Outstanding | 19.62% | 19.52% | 32.58% | 79.20% | 207.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |